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Background. Polymorphisms in IFNL3 and IFNL4, the genes encoding interferon λ3 and interferon λ4, respec-
tively, have been associated with reduced hepatitis C virus clearance. We explored the role of such polymorphisms on
the incidence of cytomegalovirus (CMV) infection in solid-organ transplant recipients.
Methods. White patients participating in the Swiss Transplant Cohort Study in 2008–2011 were included. A
novel functional TT/-G polymorphism (rs368234815) in the CpG region upstream of IFNL3 was investigated.
Results. A total of 840 solid-organ transplant recipients at risk for CMV infection were included, among whom 373
(44%) received antiviral prophylaxis. The 12-month cumulative incidence of CMV replication and disease were 0.44 and
0.08 cases, respectively. Patient homozygous for the minor rs368234815 allele (−G/−G) tended to have a higher cumu-
lative incidence of CMV replication (subdistribution hazard ratio [SHR], 1.30 [95% conﬁdence interval {CI}, .97–1.74];
P = .07), compared with other patients (TT/TT or TT/−G). The association was signiﬁcant among patients followed by a
preemptive approach (SHR, 1.46 [95% CI, 1.01–2.12]; P = .047), especially in patients receiving an organ from a seropos-
itive donor (SHR, 1.92 [95% CI, 1.30–2.85]; P = .001), but not among those who received antiviral prophylaxis (SHR, 1.13
[95% CI, .70–1.83]; P = .6). These associations remained signiﬁcant in multivariate competing risk regression models.
Conclusions. Polymorphisms in the IFNL3/4 region inﬂuence susceptibility to CMV replication in solid-organ
transplant recipients, particularly in patients not receiving antiviral prophylaxis.
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Cytomegalovirus (CMV) infection remains one of the
most common infectious complications after solid-organ
transplantation [1]. Several risk factors for the develop-
ment of CMV infection have been described, with the
donor (D) and recipient (R) serostatus at the time of
transplantation being themain determinant for predicting
the risk for subsequent CMV infection [2].Additional risk
factors include the type and dose of immunosuppressive
drug used and previous occurrence of acute rejection [3].
Despite advances in the prevention of CMV replication
after transplantation, a signiﬁcant number of recipients
may still develop CMV disease, even in the absence of
the risk factors mentioned above [4].
While it is widely accepted that the adaptive immune
response is essential in the control of CMV replication,
Received 21 May 2014; accepted 26 September 2014; electronically published 9
October 2014.
aO. M. and A. W. contributed equally to this work.
bMembers of the study group are listed at the end of the text.
Correspondence: Oriol Manuel, MD, Infectious Diseases Service and Transplan-
tation Center, University Hospital and University of Lausanne, MP14/316, CHUV,
1011 Lausanne, Switzerland (oriol.manuel@chuv.ch).
The Journal of Infectious Diseases® 2015;211:906–14
© The Author 2014. Published by Oxford University Press on behalf of the Infectious
Diseases Society of America. All rights reserved. For Permissions, please e-mail:
journals.permissions@oup.com.
DOI: 10.1093/infdis/jiu557
906 • JID 2015:211 (15 March) • Manuel et al
particularly the speciﬁc CD8+ T-cell response against CMV [5],
the importance of innate immunity for CMV control has not
completely been determined [6]. After transplantation, when
cellular immunity is impaired because of the effect of immuno-
suppressive drugs, innate immunity may play a more prominent
role in controlling viral replication. For example, some studies
have identiﬁed that polymorphisms of genes involved in innate
immunity, such as Toll-like receptor 2 (TLR-2) [7], TLR-4, and
mannose binding lectin [8, 9], were associated with an increas-
ing incidence of CMV infection or disease after transplantation.
Type I interferon (IFN) has been long considered to be crit-
ical for immune responses to viral infections. However, type III
IFN, also called IFN-λ (IFNL), has recently been described to
share many biological functions with type I IFN and also to
have an important role in response to viral infections [10, 11].
In particular, genome-wide association studies revealed that
polymorphisms in the IFNL3/4 region exert a dramatic inﬂu-
ence on the ability to clear hepatitis C virus (HCV), either spon-
taneously [12] or in response to antiviral therapy [12–15]. A
novel TT/-G substitution (rs368234815) was recently identiﬁed
as possibly the most robust or clinically relevant marker for pre-
dicting HCV clearance [16, 17].
The potential inﬂuence of IFNL polymorphisms on control-
ling viral infections other than that due to HCV has not been
well characterized. In 2 recent studies involving solid-organ
transplant recipients and hematopoietic stem-cell transplant re-
cipients, the presence of a minor allele of IFNL3 polymor-
phisms was associated with reduced CMV replication after
transplantation [18, 19]. This was in contrast with a study in-
volving human immunodeﬁciency virus (HIV)-infected indi-
viduals at high risk fro CMV infection, in which patients
harboring the minor allele of rs368234815 had a higher inci-
dence of CMV retinitis [20]. We therefore explored the role
of this novel IFNL3/4 rs368234815 polymorphism on the inci-
dence of CMV infection and disease in a unique nationwide
prospective cohort of solid-organ transplant recipients, the
Swiss Transplant Cohort Study (STCS).
METHODS
Study Population
The STCS is a multicenter nationwide cohort study including
solid-organ transplantation performed in Switzerland from
May 2008 onward [21]. The STCS comprises 6 transplantation
centers in Switzerland. Kidney transplantation is performed in
all centers, liver and heart transplantation in 3 centers, and lung
and pancreas transplantation in 2 centers. Data on demographic
parameters, transplant type, comorbidities, immunosuppressive
treatment, antimicrobial drugs, rejection, and infectious and
noninfectious events are collected at enrollment, 6 months
after enrollment, and every 12 months after enrollment on stan-
dardized data forms by local physicians and data managers.
Speciﬁc data on CMV infection available in the STCS database
include the date of the ﬁrst episode of CMV replication and of
each episode of CMV disease, the use of antiviral drugs, and the
type of CMV event, which is classiﬁed as asymptomatic replica-
tion, viral syndrome, and probable or proven end-organ disease.
For the present study, we included all white patients trans-
planted from May 2008 to March 2011 with at least one post
transplant follow-up, a positive donor and/or recipient CMV
serostatus, DNA available for genotyping and written informed
consent for participation in the STCS. Patients who died within
24 hours of transplantation were excluded. The STCS protocol
has been approved by the Ethics Committees of all participating
centers.
Antiviral and Immunosuppressive Regimens
The antiviral preventive strategy per protocol varied among
centers and type of transplant [2]. Most CMV-seronegative pa-
tients who received transplants from seropositive donors (here-
after, “D+/R− patients”) received valganciclovir prophylaxis for
3–6 months, except in 2 transplantation programs, in which
D+/R− patients were followed preemptively. CMV-seropositive
patients who received transplants from CMV-seropositive or
CMV-seronegative donors (hereafter, “R+ patients”) were man-
aged either by preemptive therapy or antiviral prophylaxis, ac-
cording to the transplantation program, except for lung
transplant recipients, all of whom received antiviral prophylax-
is. In patients receiving antiviral prophylaxis, monitoring of
CMV replication by polymerase chain reaction (PCR) was
done after discontinuation of prophylaxis in 5 of 6 transplanta-
tion centers every 2–4 weeks for an additional 3-month period,
irrespectively of the CMV serostatus. The protocol of the pre-
emptive approach was decided by each center, but basically con-
sisted of screening for CMV DNAemia by PCR every 1–2 weeks
during the ﬁrst month after transplantation and then every 2
weeks until 3–6 months after transplantation. Five centers
used PCR in plasma, and 1 center used PCR in whole blood.
All but one center used a homemade PCR; the remaining center
used a commercial Abbott Real-Time CMV Assay. Antiviral
therapy for asymptomatic patients with CMV replication was
generally started at a cutoff of 2–3 log10 copies/mL of plasma
or 3–4 log10 copies/mL of whole blood, but this cutoff varied ac-
cording to the CMV serostatus, the time after transplantation,
and whether the patient had received lymphocyte-depleting an-
tibodies. Only results of the ﬁrst PCR positive CMV DNAemia
(and whether DNAemia was treated) were recorded in the STCS
database. Immunosuppressive regimens also varied among cen-
ters and type of organ transplant.
Genotyping of the Gene Encoding Interleukin 28B (IL-28B)
The rs368234815 polymorphism was genotyped by Competitive
Allele-Speciﬁc PCR (KASP) system (LGC Genomics, United
Kingdom), using the ABI 7500 Fast real-time thermocycler,
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according to manufacturer’s protocols (available at: http://www.
lgcgenomics.com/kaspchallenge). The KASP primers were de-
signed by Kraken assay design and workﬂow management soft-
ware (LGC Genomics). Automated allele calling was performed
using SDS software (Applied Biosystems).
Clinical Deﬁnitions
Antiviral prophylaxis was deﬁned as the initiation of ganciclovir
or valganciclovir during the ﬁrst 2 weeks after transplantation.
Patients without such prophylactic treatment who were at risk
for CMV disease (ie, D+/R− patients and R+ patients) were
considered as being managed by the preemptive approach [2].
The deﬁnition of CMV infection followed international guide-
lines [22], in which active CMV infection was deﬁned as labo-
ratory conﬁrmation of CMV replication irrespective of the
presence symptoms, and CMV disease was deﬁned as CMV
replication with corresponding signs and symptoms.
Statistical Analysis
The main end point of the study was the incidence of CMV rep-
lication (thus including asymptomatic CMV infection and
CMV disease). The cumulative incidence of CMV replication
by genetic variables was calculated by using the stcompet pro-
gram implemented in Stata (StataCorp, College Station, Texas).
The risk of CMV replication and/or disease for each genetic and
demographic variable was assessed by using a semiparametric
regression model [23], also implemented in Stata (stcrreg).
Death was considered a competing event. A stepwise multivar-
iate regression model (P < .1) was used to determine the inde-
pendent risk factors from the predicted variables. We analyzed
the incidence of CMV replication in all solid-organ transplant
recipients and in kidney transplant recipients.
RESULTS
Study Population
The characteristics of 840 patients meeting the inclusion criteria
are shown in Table 1. Overall, 373 patients (44%) received an-
tiviral prophylaxis, either with valganciclovir upfront or initially
with intravenous ganciclovir. Most patients received induction
therapy with either basiliximab (60%) or antithymocyte globu-
lins (18%) and a maintenance immunosuppressive regimen
including a calcineurin inhibitor, an antimetabolite, and corti-
costeroids. The 12-month cumulative incidence of CMV infec-
tion and disease was 0.44 and 0.08, respectively. The median
time from transplantation to CMV replication was longer in pa-
tients who received prophylaxis than in patients followed by the
preemptive approach (median, 167 days vs 40 days; P < .0001).
The baseline characteristics among kidney transplant recipi-
ents (n = 526) were similar to those of the whole study popula-
tion (n = 840).
Impact of the rs368234815 Polymorphism on CMV Replication
According to Antiviral Strategy
Overall, 102 solid-organ transplant recipients (12%) were ho-
mozygous for the minor allele of rs368234815 (−G/−G carri-
ers). The cumulative incidence of CMV replication tended to
be higher among −G/−G carriers (0.52), compared with other
patients (TT/TT or TT/−G carriers, 0.43; subdistribution haz-
ard ratio [SHR], 1.30 [95% conﬁdence interval {CI}, .97–1.74];
P = .07; Figure 1 and Table 2). The association was signiﬁcant
when considering patients followed by the preemptive approach
(SHR, 1.46 [95% CI, 1.01–2.12]; P = .047) but not when consid-
ering those who received antiviral prophylaxis (SHR, 1.13 [95%
CI, .72–1.78]; P = .6). The former association was still signiﬁ-
cant in a multivariate model (SHR, 1.57 [95% CI, 1.10–2.23];
P = .01; Table 3), after adjustment for other risk factors associ-
ated with CMV replication in solid-organ transplant recipients
not receiving prophylaxis, including recipient age, donor/recip-
ient CMV serostatus, transplanted organ type, as well as induc-
tion and maintenance immunosuppressive regimen. In patients
with asymptomatic CMV replication, the presence of the minor
allele of rs368234815 had no inﬂuence on the rate of patients
who required antiviral therapy (P = .5).
Results were similar when kidney transplant recipients were
analyzed separately. Among kidney recipients followed by a pre-
emptive approach, −G/−G carriers had a higher cumulative in-
cidence of CMV replication, compared with TT/TT and TT/−G
carriers (SHR, 1.76 [95% CI, 1.10–2.84]; P = .02; Figure 1). This
association was still observed in the multivariate analysis, in
which −G/−G carriage was still associated with CMV replica-
tion (SHR, 1.78 [95% CI, 1.18–2.69]; P = .006; data not shown).
However, no association between the rs368234815 polymor-
phism and CMV replication was detected among kidney trans-
plant recipients receiving antiviral prophylaxis (SHR, 1.11 [95%
CI, .65 −1.89]; P = .7; data not shown).
There was no association between the rs368234815 polymor-
phism and CMV disease in solid-organ transplant recipients
(−G/−G vs TT/TT and TT/−G; P = .4) and in kidney transplant
recipients (P = 1.0; Supplementary Figure 1).
Impact of the rs368234815 Polymorphism on CMV Replication,
According to CMV Serostatus
We also analyzed the role of the rs368234815 separately, ac-
cording to CMV serostatus. Among D+ solid-organ transplant
and kidney transplant recipients who were followed by a pre-
emptive approach, −G/−G carriers had a higher cumulative in-
cidence of CMV replication, compared with the other patients
(all transplant recipients: SHR, 1.92 [95% CI, 1.30–2.85;
P = .001]; kidney transplant recipients: SHR, 2.28 [95% CI,
1.40–3.71; P = .0009]; Figure 2). These associations remained
signiﬁcant in the multivariate Cox regression models, after ad-
justment for relevant covariates (transplant recipients: SHR,
2.06 [95% CI, 1.40–3.01; P < .0001]; for kidney transplant
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Table 1. Baseline Characteristics of Cytomegalovirus (CMV)–Seronegative Patients Who Received Transplants From Seropositive
Donors (D+R−) and CMV-Seropositive Patients Who Received Transplants From CMV-Seropositive (D+R+) or CMV-Seronegative
(D−R+) Donors
Variable SOT Recipients (n = 840)a Kidney Transplant Recipients (n = 526)
Age, y
Recipient 54 (18) 54 (20)
Donorb 53 (22) 53 (20)
Recipient sex
Male 534 (64) 336 (64)
Female 306 (36) 191 (36)
White ethnicity 840 (100) 526 (100)
Transplanted organ
Kidney 493 (59) 493 (94)
Liver 163 (19) . . .
Lung 78 (9) . . .
Heart 56 (7) . . .
Pancreas/islets/small bowelc 17 (2) . . .
Combinedd 33 (4) 33 (6)
Donor type
Deceased 629 (75) 325 (62)
Living related and unrelated 211 (25) 201 (38)
HLA full mismatche 294 (59) 209 (52)
CMV serostatus
D+/R− 218 (26) 134 (26)
D−/R+ 263 (31) 159 (30)
D+/R+ 359 (43) 235 (44)
Induction therapyf
Basiliximab 488 (60) 308 (62)
Antithymocyte globulin 143 (18) 88 (18)
None 179 (22) 103 (21)
Maintenance regimeng
Tacrolimus 495 (65) 379 (77)
Cyclosporine 205 (27) 100 (20)
MMF/MPA 616 (81) 429 (87)
Azathioprine 22 (3) 16 (3)
mTOR inhibitors 52 (7) 11 (2)
Corticosteroids 517 (68) 366 (74)
CMV management approach
Prophylaxis 373 (44) 248 (47)
Preemptive 467 (56) 278 (53)
Acute rejection episode (12-mo cumulative incidence) 259 (31) 134 (25)
CMV infection, cases, no. (12-mo cumulative incidence) 0.44 0.47
CMV disease, cases, no. (12-months cumulative incidence) 0.08 0.08
IFNL3/4 −G/−G 102 (12) 61 (12)
Data are median value (interquartile range) or number (%) of patients, unless otherwise indicated.
Abbreviations: CMV, Cytomegalovirus; IFNL3/4, interferon λ3 and interferon λ4; IQR, interquartile range; MMF, mycophenolate mofetil; MPA, mycophenolic acid;
mTOR, mammalian target of rapamycin; SOT, solid-organ transplant.
a Among 1119 white individuals enrolled in the Swiss Transplant Cohort Study genetic analysis, 279 were excluded because the CMV serostatus of the donor and
recipient was negative (n = 253), results of CMV serologic analysis were missing or incomplete (n = 13), death occurred within 24 hours of transplantation (n = 7), or
the IFNL3/4 genotype was missing (n = 6).
b Donor age was missing for 163 solid organ transplant recipients and 0 kidney recipients.
c Including 12 islet, 4 pancreas, and 1 small bowel transplants.
d Including 19 kidney-pancreas, 6 kidney-liver, 4 kidney-kidney, 2 kidney-islets, 1 kidney-lung, and 1 kidney-kidney-pancreas transplants.
e Data were missing for 341 SOT recipients and 124 kidney transplant recipients.
f Data were missing for 30 SOT recipients and 27 kidney transplant recipients.
g Treatment at 12 months was assessable for 763 SOT recipients and 494 kidney transplant recipients.
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recipients: SHR, 2.24 [95% CI, 1.40–3.58; P = .001], respectively;
Supplementary Table 1). Again, no signiﬁcant associations were
observed among patients receiving antiviral prophylaxis (trans-
plant recipients: P = .053; kidney transplant recipients: P = .2;
Figure 2).
DISCUSSION
In this nationwide cohort study of solid-organ transplant recip-
ients, we assessed the potential inﬂuence of polymorphisms in
the IFNL3/4 region on the incidence of CMV replication. We
found that the TT/-G rs368234815 substitution, which was re-
cently identiﬁed as the best predictor of HCV clearance [16, 17],
was an independent risk factor for developing CMV replication,
speciﬁcally in the group of patients not receiving antiviral pro-
phylaxis. This was also found for kidney transplant recipients in
particular, a more homogeneous group of solid-organ trans-
plant recipients in terms of immunosuppression and antiviral
strategies. We did not observe any difference in the develop-
ment of CMV disease between patients with and those without
rs368234815, probably because of the overall low incidence of
CMV disease in our cohort.
While extensive literature exists on the role of IFNL3/4 poly-
morphisms in inﬂuencing spontaneous or treatment-induced
clearance of HCV [12, 13, 15], there are few data assessing a
potential association between such polymorphisms and CMV
replication, particularly in the transplant recipients. In a recent
study of 151 hematopoietic stem-cell transplant recipients,
donor carriage of the minor TT genotype of IFNL3 rs12979860
(a SNP in strong linkage disequilibrium with rs368234815) was
associated with a shorter duration of CMV replication in the
recipient [18]. However, no differences in the overall incidence
of CMV infection were observed according to this SNP. In a
study of 38 D+R− solid-organ transplant recipients, the
minor G allele of rs8099917 (which is also in linkage disequili-
brium with rs368234815) was associated with a lower risk of
CMV replication after discontinuation of antiviral prophylaxis
[19]. Finally, in concordance with our data, we found that the
same rs368234815 polymorphism was signiﬁcantly associated
with the occurrence of CMV retinitis in a cohort of 1217 of
HIV-infected individuals at risk (HR, 2.54 [95% CI, 1.20–
5.40]; P = .02) [20]. Discrepancies between studies may be ex-
plained by several factors, including the use of different study
populations and/or groups at risk and the differences in sample
size.
The exact mechanisms by which rs368234815 may inﬂuence
susceptibility to CMV replication among solid-organ transplant
recipients receiving no antiviral prophylaxis are not well estab-
lished. However, increasing evidence suggests that IFNLs con-
tribute to antiviral responses against viruses other than HCV.
The antiviral activity of IFNLs was highlighted in a series of
cell culture models, including herpesvirus infection [24–27].
In an intestinal cell model of CMV infection, IFNL1 and
IFNL3 were shown to activate STAT1, thereby inducing the pro-
duction of antiviral proteins and inhibiting the expression of
CMV [28]. The administration of recombinant IFNLs inhibited
replication in mice models of herpes simplex virus infections
[26], thereby conﬁrming the role of these molecules in vivo.
However, blockade of the IL-28 R1 subunit of the IL-28B recep-
tor was recently reported to decrease CMV replication in fore-
skin ﬁbroblast [19]. The rs368234815 polymorphism was
associated with reduced HCV clearance in peripheral blood
Figure 1. Cumulative incidence of cytomegalovirus (CMV) replication, according to prophylaxis and transplanted organ, in patients homozygous for the
minor allele of rs368234815 (−G/−G carriers), compared with TT/TT or TT/−G carriers. A semiparametric regression model published by Fine and Gray [23]
was used to evaluate the relative hazards associated with demographic factors or genetic variants and the end points. Proportions denote the number of
patients with CMV infection/total number of patients in the group. Abbreviation: IFNL3/4, interferon λ3 and interferon λ4.
910 • JID 2015:211 (15 March) • Manuel et al
mononuclear cells (PBMCs) stimulated with poly(I:C) [17]. It
was also associated with the expression of a novel IFNL ana-
logue, IFNL4, that exerts antiviral activities similar to those of
other type I and type III IFNs in vitro [16, 29]. Therefore, in-
creased CMV events among solid-organ transplant recipient
carrying rs368234815 may be due in part to insufﬁcient
IFNL3 expression or to the expression of IFNL4 itself. Yet the
reason why the expression of IFNL4 would be associated with
increased rather than decreased viral replication in vivo remains
to be elucidated [30]. In a mouse model of lymphocytic chorio-
meningitis virus (LCMV), differences in the IFN-stimulated
gene background were observed in acute versus latent infection,
determining the control of LCMV replication [31]. Further in-
vestigations are needed to understand the exact role of IFNL3
and IFNL4 in antiviral immune responses.
An important ﬁnding of our study is that the inﬂuence of
IFNL3/4 polymorphisms on CMV replication disappeared
when considering patients receiving CMV prophylaxis. A plau-
sible hypothesis is that, in patients managed by the preemptive
approach, CMV replication develops earlier and more fre-
quently after transplantation than in patients receiving antiviral
prophylaxis. As cell-mediated immunity is impaired after trans-
plantation, the role of innate immunity might be more evident
when viral replication occurs early and more often after trans-
plant receipt. This concords with previous studies evaluating
the role of natural killer immunoglobulin-like receptor poly-
morphisms, in which the inﬂuence of such polymorphisms in
determining CMV replication was signiﬁcant also during the
ﬁrst 3 months after transplantation but decreased over time
[32]. We also found that donor CMV serostatus was more
Table 2. Univariate Analysis of Risk Factors for the Development of Cytomegalovirus (CMV) Replication in CMV-Seronegative Patients
Who Received Transplants From Seropositive Donors (D+R−), CMV-Seropositive Patients Who Received Transplants From CMV-
Seropositive (D+R+) or CMV-Seronegative (D−R+) Donors, Overall and for Patients Not Receiving Antiviral Prophylaxis
Variable
All Patients
(n = 840)
Patients Not Receiving Antiviral
Prophylaxis (n = 467)
SHR (95% CI)a P Value SHR (95% CI)a P Value
Recipient age, per 10-y increase 1.12 (1.04–1.21) .003 1.11 (1.01–1.22) .02
Donor age, y 1.03 (.96–1.11) .4 1.05 (.96–1.14) .3
Recipient male sex 0.97 (.79–1.20) .8 0.99 (.75–1.31) 1.0
Transplanted organ
Kidney Reference Reference
Liver 0.79 (.58–1.07) .13 0.58 (.41–.82) .002
Other/combined 0.83 (.64–1.07) .15 0.85 (.58–1.24) .4
HLA full mismatch 1.17 (.90–1.52) .2 1.15 (.82–1.62) .4
Rejection episode 1.05 (1.01–1.09) .007 1.04 (.98–1.11) .18
CMV serostatus
D+/R− Reference Reference
D−/R+ 0.81 (.61–1.08) .15 0.85 (.54–1.32) .5
D+/R+ 1.33 (1.04–1.69) .02 1.53 (1.03–2.28) .04
Induction therapy
None Reference Reference
Basiliximab 1.03 (.78–1.35) .9 1.15 (.83–1.58) .4
Antithymocyte globulin 1.19 (.86–1.65) .3 1.99 (1.29–3.08) .002
Maintenance regimen
Tacrolimus 0.97 (.94–1.01) .13 0.94 (.87–1.00) .06
Cyclosporine 1.05 (1.01–1.08) .01 1.09 (1.01–1.17) .02
MMF/MPA 1.08 (1.02–1.14) .009 1.10 (.99–1.22) .08
mTOR inhibitors 0.99 (.90–1.09) .8 0.97 (.83–1.14) .7
Corticosteroids 1.12 (1.04–1.21) .003 1.33 (1.01–1.76) .04
Exposure to antiviral drugb 0.90 (.81–0.99) .02 0.96 (.78–1.18) .7
IFNL3/4 -G/-Gc 1.30 (.97–1.74) .07 1.46 (1.01–2.12) .047
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; IFNL3/4, interferon λ3 and interferon λ4; MMF, mycophenolate mofetil; MPA, mycophenolic acid;
mTOR, mammalian target of rapamycin.
a The subdistribution hazard ratio (SHR) was calculated using the semiparametric regression model published by Fine and Gray [23].
b Risk of CMV infection during concurrent exposure to valganciclovir or ganciclovir.
c Genetic association with rs368234815 is for recessive mode of inheritance (patients homozygous for the rare alleles [−G/−G] are compared to the other patients
[TT/TT and TT/−G]).
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important than recipient CMV serostatus in determining the
inﬂuence of the IFNL variants. Actually, a wide majority of pa-
tients harboring the rs368234815 polymorphism who received
an organ from a seropositive donor developed CMV replication
independently, whether they were R− or R+. These data suggest
that new CMV strains transmitted by the donor [33] may be
more difﬁcult to control in recipients harboring the rs368234815
polymorphism.
Our study have some limitations. First, because data from
only the ﬁrst episode of asymptomatic CMV replication were
recorded in the STCS database, we were not able to investigate,
in the present study, whether the IFNL3/4 polymorphisms had
an impact on the overall duration of CMV infection and, par-
ticularly, on the response to antiviral therapy. Second, patients
who received antiviral therapy were not monitored for CMV
replication by use of the same schedule as that for patients
managed by the preemptive approach just after transplantation;
this difference could partially account for the different impact of
the IFNL3/4 polymorphisms on CMV replication observed
according to the preventive strategy used. Third, the low num-
ber of CMV disease events prevented us from drawing any con-
clusion about a potentially higher risk of progression from
asymptomatic viral replication to overt CMV disease in patients
with −G/−G carriage. Fourth, the association between CMV
replication and the IFNL3 polymorphism was observed for
the recessive mode of inheritance, while the association ob-
served among HCV-infected patients is usually dominant.
This difference may be due to some threshold effect of the
amount of IFNL3/4 in response to speciﬁc pathogens. The re-
cessive model was chosen in a post hoc analysis, which could
also be a limitation of our study. Finally, the prevention strate-
gies and immunosuppressive regimens were somewhat variable
Table 3. Multivariate Analysis of Risk Factors for the Development of (CMV) Replication in CMV-Seronegative Patients Who Received
Transplants From Seropositive Donors (D+R−), CMV-Seropositive Patients Who Received Transplants From CMV-Seropositive (D+R+) or
CMV-Seronegative (D−R+) Donors, Overall and for Patients Not Receiving Antiviral Prophylaxis
Factor
All Patients (n = 840)
Patients Not Receiving Antiviral
Prophylaxis (n = 455)a
SHR (95% CI)b P Value SHR (95% CI)b P Value
Recipient age, per 10-y increase 1.14 (1.06–1.23) .001 1.12 (1.02–1.24) .02
Transplanted organ
Kidney . . . Reference
Liver . . . 0.66 (.45–.98) .04
Other/combined . . . 0.66 (.42–1.04) .07
CMV serostatus
D+/R− Reference Reference
D−/R+ 0.75 (.56–1.01) .06 0.91 (.55–1.49) .7
D+/R+ 1.29 (.01–1.70) .04 1.60 (1.02–2.60) .04
Induction therapy
None . . . Reference
Basiliximab . . . 1.14 (.82–1.58) .5
Antithymocyte globulin . . . 2.08 (1.21–3.57) .008
Acute rejection 1.05 (1.02–1.09) .005 . . .
Maintenance therapy
Corticosteroids 1.13 (1.04–1.22) .003 1.31 (1.01–1.70) .04
Tacrolimus 0.91 (.84–.99) .02
MMF/MPA 1.07 (1.01–1.13) .02 . . .
Cyclosporine 1.08 (1.04–1.12) <.0001 . . .
Exposure to antiviral drugc 0.85 (.77–.93) .001 . . .
IFNL3/4 -G/-Gd 1.32 (.99–1.75) .06 1.57 (1.10–2.23) .01
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; IFNL3/4, interferon λ3 and interferon λ4; IQR, interquartile range; MMF, mycophenolate mofetil; MPA,
mycophenolic acid.
a The number of patients in the multivariate analyses (n = 455) is slightly lower than the number of patients included in the univariate analysis (n = 467) because of
missing data on induction therapy for 12 patients.
b The subdistribution hazard ratio (SHR) was calculated using the semiparametric regression model published by Fine and Gray [23]. Covariates with a P value of < .1
were kept in the multivariate analyses.
c Risk of CMV infection during concurrent exposure to valganciclovir or ganciclovir.
d Genetic association with rs368234815 is for recessive mode of inheritance (patients homozygous for the rare alleles [−G/−G] are compared to the other patients
[TT/TT and TT/−G]).
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among transplantation programs, so it is possible that some re-
maining biases speciﬁcally related to the transplantation center
were not corrected by the multivariate analysis. Nevertheless,
because of the large number of patients included, the strict
and homogeneous deﬁnitions used for CMV infection, and
the use of a novel polymorphism with predicted functional ac-
tivity, the data indicate novel evidence of a relationship between
IFNL polymorphisms and CMV infection.
In conclusion, in this large cohort of solid-organ transplant
recipients, we found that CMV infection in patients not receiv-
ing antiviral prophylaxis was inﬂuenced by IFNL genetic vari-
ants. This effect was stronger in recipients who received an
allograft from a CMV-seropositive donor. These results indicate
that the INFL rs368234815 polymorphism might be considered
a novel risk factor for developing CMV-associated complica-
tions after organ transplantation. Validation of this association
in further clinical studies has the potential to improve risk strat-
iﬁcation for CMV reactivation and eventually inﬂuence future
prevention strategies and guidelines, particularly in patients fol-
lowed up by the preemptive approach.
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Figure 2. Cumulative incidence of cytomegalovirus (CMV) replication, according to antiviral preventive strategy, in patients who received solid-organ
transplants and kidney transplants from CMV-seropositive donors (D+) and were homozygous for the minor allele of rs368234815 (−G/−G carriers), com-
pared with TT/TT or TT/-G carriers. A semiparametric regression model published by Fine and Gray [23] was used to evaluate the relative hazards associated
with the demographic factors or genetic variants and the end points. Proportions denote the number of patients with CMV infection/total number of patients
in the group. Abbreviation: IFNL3/4, interferon λ3 and interferon λ4.
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